PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
NCT03817320
Active Not Recruiting
This is a phase 1/2 study of a drug called Ixazomib in combination with cytotoxic chemotherapy consisting of Vincristine, Dexamethasone, Asparaginase, and Doxorubicin (VXLD).
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
02/20/2024
Locations: C.S. Mott Children's Hospital, Ann Arbor, Michigan
Conditions: ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood
Register for Updates
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
NCT00520767
Completed
RATIONALE: Giving bortezomib together with melphalan and dexamethasone may be an effective treatment for primary amyloidosis and light chain deposition disease. PURPOSE: This phase II trial is studying how well giving bortezomib together with melphalan and dexamethasone works in treating patients with primary amyloidosis or light chain deposition disease.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/20/2023
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan +2 locations
Conditions: Primary Systemic Amyloidosis, Light Chain Deposition Disease
Register for Updates
Expanded Access Treatment Protocol CA204-143
NCT02368301
No Longer Available
The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at U.S. sites where licensed physicians determine clinical need.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Multiple Myeloma
Register for Updates
Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma
NCT02004275
Active Not Recruiting
This randomized phase I/II trial studies the side effects and best dose of pomalidomide and ixazomib when given together with dexamethasone and to see how well pomalidomide and dexamethasone with or without ixazomib works in treating patients with multiple myeloma that has come back. Biological therapies, such as pomalidomide and dexamethasone, may stimulate the immune system in different ways and stop cancer cells from growing. Ixazomib may stop the growth of cancer cells by blocking some of th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/09/2023
Locations: Hickman Cancer Center, Adrian, Michigan +61 locations
Conditions: Multiple Myeloma in Relapse
Register for Updates
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
NCT03719105
Recruiting
Patients are in 2 cohorts: Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymphoma and leukemia Cohort 2: combining pralatrexate (PRX) (Cycles 1, 2, 4, 6) and brentuximab vedotin (BV) (Cycles 3, 5) to cyclophosphamide, doxorubicin, and prednisone in children, adolescent, and young adults with advanced peripheral T-cell lymphoma (non-anap... Read More
Gender:
ALL
Ages:
Between 1 year and 31 years
Trial Updated:
10/24/2023
Locations: Helen De Vos, Grand Rapids, Michigan
Conditions: NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma
Register for Updates
Dexamethasone Administered Via the Epidural Catheter as an Adjunct in Patients Undergoing Cesarean Delivery
NCT03877549
Withdrawn
This study will evaluate the ability of dexamethasone to enhance labor epidurals when administered as an adjunct to local anesthetics via an epidural catheter. Patients undergoing elective cesarean sections will be randomized into three groups, each receiving the same combined spinal epidural (CSE). At surgical closure, Group 1 will receive 10cc bupivacaine 0.0625%, Group 2 will receive 10cc bupivacaine 0.0625% +4mg dexamethasone, and Group 3 will receive 10cc bupivacaine 0.0625% + 8mg dexametha... Read More
Gender:
FEMALE
Ages:
Between 18 years and 55 years
Trial Updated:
09/22/2023
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: Post Operative Pain
Register for Updates
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
NCT01850524
Completed
The purpose of this study is to provide continued access to ixazomib and/or lenalidomide to participants who are continuing to have clinical benefit and to continue collecting relevant safety data to monitor safety in participants with Newly Diagnosed Multiple Myeloma (NDMM) who are not eligible for stem cell transplant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/20/2023
Locations: Not set, Ann Arbor, Michigan +2 locations
Conditions: Multiple Myeloma
Register for Updates
Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial
NCT02623426
Completed
The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial will compare the relative efficacy and safety of intravitreal methotrexate, intravitreal ranibizumab, and the intravitreal dexamethasone implant for the treatment of uveitic macular edema persisting or reoccurring after an intravitreal corticosteroid injection. MERIT is a parallel design (1:1:1), randomized comparative trial with an anniversary close-out after 6 months of follow-up. The primary outcome is perce... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan
Conditions: Uveitis, Macular Edema
Register for Updates
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
NCT00335140
Terminated
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving ritu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/14/2023
Locations: Borgess Medical Center, Kalamazoo, Michigan +2 locations
Conditions: Lymphoma
Register for Updates
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
NCT00060398
Completed
RATIONALE: Epoetin alfa may stimulate red blood cell production and may help improve cancer-related anemia and fatigue. Steroid therapy with dexamethasone may increase the effectiveness of epoetin alfa. It is not yet known if epoetin alfa is more effective with or without dexamethasone in treating anemia-related fatigue in patients with prostate cancer. PURPOSE: This randomized phase III trial is studying epoetin alfa and dexamethasone to see how well they work compared to epoetin alfa alone in... Read More
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
06/14/2023
Locations: St. Joseph Mercy Cancer Center at St. Joseph Mercy Hospital, Ann Arbor, Michigan +10 locations
Conditions: Anemia, Fatigue, Prostate Cancer
Register for Updates
Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission
NCT00002514
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well... Read More
Gender:
ALL
Ages:
Between 15 years and 65 years
Trial Updated:
06/14/2023
Locations: Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan +12 locations
Conditions: Leukemia
Register for Updates
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
NCT01734928
Completed
The purpose of this study is to compare the efficacy of the combination of pomalidomide, bortezomib and low dose dexamethasone to the combination of bortezomib and low dose dexamethasone in participants with relapsed/refractory multiple myeloma. This study will also assess how safe the combination of pomalidomide, bortezomib and low dose dexamethasone is compared to the combination of bortezomib and low dose dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2023
Locations: Henry Ford Medical Center - New Center One, Detroit, Michigan +4 locations
Conditions: Multiple Myeloma
Register for Updates